Printer Friendly


 WHIPPANY, N.J., Oct. 26 /PRNewswire/ -- Isomedix Inc. (NASDAQ: ISMX) today reported a 21 percent increase in third quarter consolidated sales to a record $11,269,841 compared with sales of $9,323,215 for the same period in 1992. Sales for the third quarter increased 4 percent over 1993 second quarter sales of $10,805,461.
 Consolidated operating income of $3,495,548 for the third quarter represented a 12 percent increase over the 1992 operating income of $3,122,504 and an 8 percent increase over the 1993 second quarter operating income of $3,223,475.
 As previously announced, fixed costs associated with the opening of the company's new EtO expansion at its Northborough, Mass. facility and Chester, N.Y. gamma facility, coupled with low initial utilization of these facilities due to delays in validation, resulted in consolidated net income for the third quarter increasing a modest 3 percent to $2,103,837 compared with $2,037,844 a year ago. However, consolidated not income for the third quarter 1993 when compared to second quarter 1993 net income of $1,950,077 increased 8 percent reflecting in part increased utilization of these two new facilities. Based on a weighted average of 7,349,085 common shares outstanding in the third quarter compared with 7,138,649 shares a year ago, an increase of 3 percent, earnings per share were 29 cents for both periods. Earnings per share were up 12 percent over earnings in the 1993 second quarter of 26 cents per share based on a weighted average of 7,334,899 common shares outstanding.
 Consolidated sales for the nine months ended Sept. 30, 1993 increased 16 percent to $31,647,959 compared with $27,182,073 for the same period in 1992. Operating income increased 12 percent to $9,367,555 compared to $8,401,661 for the 1992 period. The 1992 period included a non-recurring expense of approximately $268,000 resulting from the prepayment of an industrial development revenue bond.
 For the reasons described above, consolidated net income for the nine months ended Sept. 30, 1993, increased 3 percent to $5,723,758 compared with $5,580,043 earned a year ago. Another contributing factor was that in 1992 Isomedix received non-recurring interest income of approximately $370,000 ($229,400 after tax) on a tax refund. Based on a weighted average of 7,350,502 common shares outstanding in 1993 compared with 7,126,855 shares a year ago, an increase of 3 percent, earnings per share were 78 cents for both periods.
 Isomedix Inc. operates a network of 10 sterilization facilities in eight states and Canada. The capability to sterilize medical devices with pure ethylene oxide has been added at three of the gamma facilities. The company also provides validation services through its Skyland Scientific Services subsidiary located in Montana.
 Comparative Tables
 Periods ended Three Months Nine Months
 Sept. 30 1993 1992 1993 1992
 Sales $11,269,841 $9,323,215 $31,647,959 $27,182,073
 Operating income 3,495,548 $3,122,504 9,367,555 8,401,661
 Net income 2,103,837 2,037,844 5,723,758 5,580,043
 Earnings per share $.29 $.29 $.78 $.78
 Weighted average
 number of shares
 outstanding 7,349,085 7,138,649 7,350,502 7,126,855
 -0- 10/26/93
 /CONTACT: Thomas J. DeAngelo, chief operating officer of Isomedix, 201-887-4700/

CO: Isomedix Inc. ST: New Jersey IN: HEA SU: ERN

LG-CK -- NY079 -- 6834 10/26/93 13:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 26, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters